MedTrace Logo

Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes Mellitus

NCT06532578 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-04-15

No results posted yet for this study

Summary

The study is designed to evaluate the preliminary efficacy, safety, population PK profile, and immunogenicity of CPX101 in subjects with obesity or overweight with weight related comorbidities but without diabetes mellitus.

Conditions

  • Overweight and Obesity

Interventions

BIOLOGICAL

CPX101 or placebo 120mg Q2W

Subcutaneous injection of CPX101 or placebo

BIOLOGICAL

CPX101 or placebo 160mg Q4W

Subcutaneous injection of CPX101 or placebo

BIOLOGICAL

CPX101 or placebo 160mg Q2W

Subcutaneous injection of CPX101 or placebo

BIOLOGICAL

CPX101 or placebo 240mg Q4W

Subcutaneous injection of CPX101 or placebo

BIOLOGICAL

CPX101 or placebo 240mg Q2W

Subcutaneous injection of CPX101 or placebo

BIOLOGICAL

CPX101 or placebo 320mg Q2W

CPX101 or placebo 320mg Q2W

BIOLOGICAL

CPX101 or placebo 360mg Q4W

CPX101 or placebo 360mg Q4W

Sponsors & Collaborators

  • Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-13
Primary Completion
2025-12-15
Completion
2026-04-01

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06532578 on ClinicalTrials.gov